Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status

Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) tests are commonly used to assess human epidermal growth factor 2 (HER2) status of tumors in patients with breast cancer. This analysis evaluates the likely cost‐effectiveness of expanded retesting to assess HER2 tumor status in women with early stage breast cancer.

[1]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[2]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[3]  Shujie Yang,et al.  Abstract 71: Knockdown of MTDH increases drug sensitivity to HDAC inhibitor and TRAIL combination treatment in endometrial cancer cells , 2011 .

[4]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[5]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Buxton,et al.  Does Medicare Have an Implicit Cost-Effectiveness Threshold? , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Perez,et al.  Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. , 2012, Journal of the National Cancer Institute.

[9]  E. Perez,et al.  HER2-Positive Breast Cancer: Current Treatment Strategies , 2008, Cancer investigation.

[10]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[11]  Mitch Dowsett,et al.  Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Ross,et al.  Saving lives with accurate HER2 testing. , 2010, American journal of clinical pathology.

[13]  Jong-Hyeon Jeong,et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Andrew H. Briggs,et al.  Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.

[15]  S. Levine,et al.  The Cost-Effectiveness of Primary Stroke Centers for Acute Stroke Care , 2012, Stroke.

[16]  Peter A. Kaufman,et al.  P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry. , 2011 .

[17]  E. Perez,et al.  Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) , 2013, Breast Cancer Research and Treatment.

[18]  Holger Moch,et al.  Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies , 2010, Breast Cancer Research and Treatment.

[19]  Marta Cuadros,et al.  Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[20]  K. Allison,et al.  Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. , 2010, American journal of clinical pathology.

[21]  James N Ingle,et al.  HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. , 2002, Mayo Clinic proceedings.

[22]  D. Lubeck,et al.  Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer , 2007, Cancer.

[23]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[24]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[25]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[26]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[27]  H. Rugo,et al.  The cardiac safety of trastuzumab in the treatment of breast cancer , 2010, Expert opinion on drug safety.

[28]  Nandini Dendukuri,et al.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.